RecruitingNCT07419347
Study of Glecaprevir/Pibrentasvir to Assess Safety Through Real-World Data
Retrospective Analysis of Glecaprevir/Pibrentasvir Safety and Concomitant Medications Through Integrated Real-World Data
Sponsor
AbbVie
Enrollment
2,000 participants
Start Date
Feb 27, 2026
Study Type
OBSERVATIONAL
Conditions
Summary
The objective of this study is to assess the safety, tolerability and effectiveness of 8-week Glecaprevir/Pibrentasvir (G/P) in participants taking either prescribed or illicit drugs.
Eligibility
Min Age: 18 Years
Inclusion Criteria3
- Prescribed 8 weeks of Glecaprevir/Pibrentasvir (G/P).
- Treatment-naïve (for the current infection, participants that may have had prior infections which were resolved with treatment are considered naive for current infection as long as they have not received any treatment for the current infection.)
- Is concomitantly on one or more prescription medications or illicit drugs.
Exclusion Criteria4
- Treated with DAAs other than G/P.
- History of decompensated cirrhosis.
- Had Hepatitis-B virus (HBV) infection.
- Had hepatocellular carcinoma (HCC).
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(2)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07419347